Sundrug Co (9989) AI Stock Analysis

• Market Cap: ¥447.23B
• Dividend Yield: 3.04%
• Average Volume (3M): 271.71K
• Price to Earnings (P/E): 14.1
• Beta (1Y): 0.31
• Revenue Growth: 6.32%
• EPS Growth: 8.19%
• Country: JP
• Employees: 6,662
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 76.61
• Shares Outstanding: 119,331,184
• 10 Day Avg. Volume: 294,250
• 30 Day Avg. Volume: 271,706
• PEG Ratio: 2.88
• Price to Book (P/B): 1.83
• Price to Sales (P/S): 0.61
• P/FCF Ratio: 63.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥4,720.00
• Price Target Upside: 14.09% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 294.1
• Revenue Forecast (FY): ¥912.76B

• Rating: 69 Neutral
• Price Target: ¥4,223.00 ▲(2.08% Upside)
• Action: Downgraded Date: 09/13/25
• Date: Action: Downgraded 09/13/25

Sundrug Co's strong financial performance is the primary driver of its stock score, supported by consistent revenue growth and solid balance sheet metrics. However, technical indicators suggest bearish momentum, which weighs down the overall score. The valuation is reasonable, providing some support to the stock's attractiveness.

Positive Factors

Balance sheet strength

A very low debt-to-equity ratio (0.14) and a high equity ratio (~60.7%) provide durable financial flexibility. This capital structure reduces refinancing risk, supports investment or organic store expansion, and helps absorb sector shocks while sustaining shareholder returns over the medium term.

Negative Factors

Slim net margin

A modest net margin (~3.8%) leaves limited buffer against rising input, logistics, or wage costs common in retail. Sustained margin pressure or pricing constraints could materially compress profits, reducing room for reinvestment or dividend increases over the medium term.

Sundrug Co Business Overview & Revenue Model

Company Description

Sundrug Co.,Ltd. operates and manages drug stores and dispensing pharmacies in Japan. It also operates discount stores that offers food, cosmetics, home appliances, clothing, car supplies, sports and goods, alcoholic beverages, and pharmaceutical ...

Read more

Sundrug Co.,Ltd. operates and manages drug stores and dispensing pharmacies in Japan. It also operates discount stores that offers food, cosmetics, home appliances, clothing, car supplies, sports and goods, alcoholic beverages, and pharmaceutical ...

How the Company Makes Money

Sundrug makes money primarily through retail sales and pharmacy-related services. (1) Drugstore retail sales: The company generates revenue from selling a broad mix of products in its stores, typically including OTC medicines, cosmetics and person...

Read more

Sundrug makes money primarily through retail sales and pharmacy-related services. (1) Drugstore retail sales: The company generates revenue from selling a broad mix of products in its stores, typically including OTC medicines, cosmetics and person...

Sundrug Co Financial Statement Overview

Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	814.94B	801.81B	751.78B	690.46B	648.73B	634.31B
Gross Profit	203.56B	186.81B	189.32B	171.95B	156.51B	158.55B
EBITDA	63.58B	61.89B	56.24B	49.52B	44.26B	46.01B
Net Income	31.40B	30.75B	29.13B	25.70B	23.85B	25.33B
Balance Sheet
Total Assets	442.27B	445.08B	421.31B	361.72B	325.77B	308.53B
Cash, Cash Equivalents and Short-Term Investments	62.98B	64.96B	69.70B	80.87B	89.33B	86.50B
Total Debt	44.22B	39.48B	35.85B	939.00M	529.00M	114.00M
Total Liabilities	172.20B	175.37B	168.21B	125.39B	105.17B	103.37B
Stockholders Equity	270.06B	269.71B	253.09B	236.33B	220.59B	205.16B
Cash Flow
Free Cash Flow	0.00	7.71B	4.76B	12.59B	12.86B	15.94B
Operating Cash Flow	0.00	41.16B	41.19B	37.38B	31.68B	31.76B
Investing Cash Flow	0.00	-35.37B	-74.85B	-28.51B	-20.66B	-17.90B
Financing Cash Flow	0.00	-10.60B	22.49B	-17.33B	-8.19B	-8.06B

Sundrug Co Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4137.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9989, the sentiment is Negative. The current price of 4137 is above the 20-day moving average (MA) of 3897.92, above the 50-day MA of 3996.18, and below the 200-day MA of 4219.90, indicating a bearish trend. The MACD of -26.66 indicates Negative momentum. The RSI at 41.40 is Neutral, neither overbought nor oversold. The STOCH value of 8.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:9989.

Sundrug Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3148	75 Outperform	¥209.25B	12.71	―	2.35%	7.55%	16.01%
9989	69 Neutral	¥447.23B	14.05	11.37%	3.04%	6.32%	8.19%
3549	67 Neutral	¥353.30B	16.82	―	0.41%	15.81%	27.05%
7649	66 Neutral	¥641.95B	14.44	15.71%	0.96%	21.81%	67.76%
3391	62 Neutral	¥959.09B	19.41	―	1.72%	―	―
3349	60 Neutral	¥505.30B	16.97	―	0.93%	3.73%	18.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Sundrug Co Corporate Events